Genitourinary Group (GETUG)

President: Prof. Stéphane CULINE, Saint-Louis Hospital, Paris

This group is accredited by the French National Cancer Institute (INCa).

 

 

French and European collaborations

  • French Association of Urology (AFU)
  • CeRePP  (Centre de Recherche sur les Pathologies Prostatiques)
  • Unicancer Oncogeriatrics Group (GERICO)
  • French Association of Supportive care in cancer (AFSOS)
  • European Organisation for Research and Treatment of Cancer (EORTC)
  • PEACE (Prostate Consortium in Europe)
  • European Society for Blood and Marrow Transplantation (EBMT)

International collaborations

Various key hospitals leaders in the genitourinary field

Strategic priorities

  • biobanking
  • proof of concept studies
  • therapeutic strategies evaluation
  • real-life data
  • medical economics 

 

Clinical trials

Since its creation in 1997, the Genitourinary Group has conducted more than 30 national and international multicentre clinitcal trials including around 6000 patients.

Recruiting clinical trials

 

 

 

 

Contact

Soazig Nenan, GETUG/GERICO/supportive care Programmes Head

 

 

Recruiting trials

Study Title: GETUG-AFU 27 – TIGER - EORTC 1407 - ALLIANCE A031102

Synopsis de TIGER

Essai randomisé de phase III comparant une chimiothérapie standard à dose conventionnelle associant du paclitaxel, à l’ifosfamide et au cisplatine (TIP) à une chimiothérapie à haute dose utilisant du paclitaxel et de l'ifosfamide pour mobiliser les cellules souches* suivie de l’association carboplatine et étoposide (TI-CE) à dose élevée comme premier traitement de rattrapage chez les patients ayant une tumeur germinale en récidive ou réfractaires.

Tumour localization: tumeurs germinales

Study coordinator: A. Fléchon

Phase: III

Number of expected patients: 50

Study start date: 01 / 10 / 16

Number of Clinical trials.gov: NCT02375204

Participating countries: Etats-Unis, Belgique, Irlande, Italie, France, Pays-Bas, Royaume Uni, Allemagne, Espagne, Slovaquie, Suisse, Danemark

 

Study Title: AFU-GETUG 21 - PEACE 1

Synopsis de PEACE 1

A prospective randomised phase III study of androgen deprivation therapy ± local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer.

Tumour localization: Prostate cancer - Metastatic stage

Study coordinator: K Fizazi, Gustave Roussy, Villejuif

Phase: III

Number of expected patients: 916

Study start date: 13 11 2013

Number of Clinical trials.gov: NCT01957436

Participating countries: FRA, ESP, IRL, BEL, DEU,  ITA, ROU, CHE

 

Study Title: GETUG-AFU 23 - PEACE 2

Synopsis de PEACE 2

A randomized phase III factorial design of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse

Tumour localization: Prostate cancer- localized stage - High risk of recurrence

Study coordinator: K Fizazi, Gustave Roussy, Villejuif

Phase: III

Number of expected patients: 1048

Study start date: 17 09 2013

Number of Clinical trials.gov: NCT01952223

Participating countries: FRA, ESP,BEL, ITA,

 

Study Title: GETUG-AFU 24 - BEVABEL           

Synopsis de BEVABEL                                                                    

Prospective phase II study of gemcitabine plus platinium salt in combination with bevacizumab (avastin®) for metastatic collecting duct carcinoma

Tumour localization: Collecting Duct Carcinoma - Metastatic stage

Study coordinator: N Pécuchet, HEGP, Paris

Phase: II

Number of expected patients: 41

Study start date: 15 12 2014

Number of Clinical trials.gov: NCT02363751

Participating countries: FRA

 

Study Title: GETUG-AFU 25 - MEGACEP

Synopsis de MEGACEP

Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatine) on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Tumour localization: Penile cancer - Metastatic lymph node involvement

Study coordinator: J Rigaud, CHU Nantes

Phase: II

Number of expected patients: 78

Study start date: 25 04 2016

Number of Clinical trials.gov: NCT02817958

Participating countries: FRA